Conclusion (177)Lutetium-prostate-specific membrane antigen-I&T therapy is effective with tolerable side effects in our local setting. Prostate-specific antigen decline >= 50% is associated with longer progression-free survival and overall survival.Thang, Sue PingLam, Winnie Wing ChuenTong, Aaron ...
Interest Based Ads PLUVICTO can help you be you for longer, giving you the chance for more everyday victories If you have advanced prostate cancer, you know every day matters. PLUVICTO could give you more time for what's important to you and your loved ones. That's a victory. ...
(psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy . what are side effects of pluvicto? pluvicto may cause serious side effects including: hives, difficulty breathing, swelling of ...
The objective of this study was to analyze the safety and efficacy of (177)Lu-labeled DOTAGA-based prostate specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifty-six mCRPC pa...
advancement for people with progressing mCRPC, as it can significantly improve survival rates for those who have limited treatment options," said Oliver Sartor, MD, Medical Director at Tulane Cancer Center. "Pluvicto is a step forward in the evolution of precision medicine for prostate cancer." ...
(lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has ...
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30. Article PubMed PubMed Central Google Scholar Grünberg J, Lindenblatt D, Dorrer H, et al. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161...
Whilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In recent years, interest in using theranostic agents to treat castrate-resistant prostate cancer (CRPC) and metastatic prostate cancer has emerged. Lu-TLX591 monoclonal...
We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with 68Ga and 177Lu, and the survival after treatment with 225Ac-PSMA-TO-1/-617 in a murine model of disseminated prostate cancer. We also report dosimetry data of 177Lu-...
Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM: Therapeutic efficacy of 177Lu-CHX-A”-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 2009, 69: 92–104. 10.1002/pros.20856 Article PubMed Central ...